'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Zydus Lifesciences has increased 17.96% to Rs 6527.9 crore. Sales of pharmaceuticals segment has gone up 18.15% to Rs 5,617.20 crore (accounting for 86.05% of total sales). Sales of Consumer Products segment has gone up 16.82% to Rs 910.70 crore (accounting for 13.95% of total sales).
Profit before interest, tax and other unallocable items (PBIT) has jumped 22.28% to Rs 1,891.60 crore. PBIT of pharmaceuticals segment rose 22.78% to Rs 1,719.60 crore (accounting for 90.91% of total PBIT). PBIT of Consumer Products segment rose 17.49% to Rs 172.00 crore (accounting for 9.09% of total PBIT).
PBIT margin of pharmaceuticals segment rose from 29.46% to 30.61%. PBIT margin of Consumer Products segment rose from 18.78% to 18.89%. Ove...
Pleaselogin & subscribe to view the full report.
More Reports
|
|